ArticleBMC cancer2026
Upregulation of Derlin 3 (DERL3) protein expression is associated with Oral Cancer progression and is independent of promoter hypermethylation.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDERL3 (Derlin 3) is a Derlin family protein involved in endoplasmic reticulum (ER) associated degradation of unfolded or misfolded glycoproteins. Our previous comprehensive genomic and transcriptomic profiling of leukoplakia and oral squamous cell carcinoma (OSCC) revealed amplification at the 22q11.23 locus, which harbours the DERL3 gene. However, DERL3 mRNA expression was found to be downregulated during disease progression, suggesting the role of epigenetic regulation.
methodsWe evaluated promoter methylation using the Quantitative real-time methylation-specific PCR technique, copy number alterations using TaqMan assays, and protein expression through immunohistochemistry. The methylation levels between normals, leukoplakia and OSCC were compared using the Kruskal–Wallis test. Correlations between different techniques were computed using Spearman's rank correlation. The indirect and direct effects of DERL3 gene amplification on methylation and protein expression were evaluated using mediation analyses. Recurrence-free survival and disease-specific survival were calculated using a log-rank test.
resultsWe observed a sequential, significant increase in promoter methylation of leukoplakia, early-stage, and advanced-stage OSCC (p-value < 0.001), compared to control tissues. The promoter methylation was inversely correlated with DERL3 gene expression. Interestingly, the protein was overexpressed in leukoplakia (p = 0.023), early-stage (p = 0.012), and advanced-stage OSCC (p < 0.001) compared to normal tissue. High protein expression correlated with advanced-stage OSCC, pathological grade and habit profile, while methylation showed a significant association with age, pathological grade and advanced-stage OSCC. However, DERL3 aberrations were not associated with patient survival.
conclusionsOur findings highlight that while promoter hypermethylation may account for reduced DERL3 mRNA expression, the concomitant increase in DERL3 protein expression suggests that additional regulatory mechanisms contribute to OSCC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.